• Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights

  • Community Resources

  • Our Expert Network

CME & EducationAbout Us
Loading...
CME & EducationAbout Us
Loading profile...
  • Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights
  • Community Resources

  • Our Expert Network
  1. Home
  2. Videos
  3. Discourses In Dermatology
  4. Addressing Touch Starvation Strategies For Improving Patient Well Being

Addressing Touch Starvation: Strategies for Improving Patient Well-Being

Featuring:
NBNicholas Brownstone, MDFaculty
AGAlexandra Golant, MDFaculty
Updated:Aug 14, 2024
Dermatology

About this video

In this episode of Topical Conversations, dermatologists Nicholas Brownstone, MD, and Alexandra K. Golant, MD, address the critical yet often overlooked issue of touch starvation, particularly affecting patients with inflammatory skin conditions. This discussion highlights how touch starvation impacts patients' overall quality of life and offers practical advice for clinicians on how to address this issue. 

Understanding touch starvation 

Touch starvation, in the context of dermatology, is a multifaceted issue with significant implications for patients with inflammatory skin diseases. From a clinical perspective, touch starvation can manifest as patients feeling isolated and less engaged with their health care providers. This reduced interaction may hinder providers from fully assessing the severity of the disease and its impact on the patient’s quality of life. Consequently, patients may suffer silently, experiencing challenges that health care providers may not fully appreciate. 

Another dimension of touch starvation involves the social and emotional isolation that often accompanies inflammatory skin conditions. This isolation can lead to various negative outcomes, such as mental health issues, social anxiety, and withdrawal from daily activities. Addressing these concerns is crucial for improving the overall well-being of patients and ensuring that clinicians are more attuned to the broader impacts of these conditions. 

Impact of touch starvation on quality of life 

Touch starvation significantly affects the quality of life for patients with conditions like psoriasis and atopic dermatitis. Patients may experience a substantial burden, which is often underreported. If clinicians do not actively inquire about quality of life, they may miss crucial insights into how the disease affects the patient's mental health, self-esteem, and interpersonal relationships. 

Many patients are not proactive in discussing their emotional distress or the extent to which their condition impacts their lives. Therefore, it is essential for health care providers to proactively assess quality of life to better understand the severity of the disease and adjust treatment plans accordingly. Inadequate recognition of touch starvation can lead to undertreatment, leaving patients with a diminished quality of life. 

Identifying touch starvation in patients 

To effectively identify touch starvation and its impact on patients, clinicians can adopt several strategies: 

  1. Frequent follow-ups: It is important to schedule more frequent visits for patients who appear to be struggling or whose condition may be worsening. Shorter follow-ups can help ensure that providers stay updated on the patient’s condition and make timely adjustments to treatment. 
  2. Intentional dialogue: During clinic visits, take the time to engage in meaningful conversations about the patient’s quality of life. Ask specific questions about how their disease affects their daily activities, sleep, and overall well-being. Open-ended questions, such as “What activities are you unable to do because of your condition?” can provide valuable insights. 
  3. Holistic care: Regular follow-ups are crucial for identifying mental health strain or comorbidities that may not be immediately apparent. A comprehensive approach to patient care can reveal underlying issues that need to be addressed alongside the primary skin condition. 

Supporting patients with low self-esteem and poor body image 

For patients experiencing low self-esteem or poor body image due to their disease, several strategies can help: 

  1. Access to advanced therapies: The advent of new treatments has provided hope for many patients. Informing patients about advanced therapeutics can offer them a sense of optimism and encourage them to engage more actively in their treatment plan. 
  2. Support groups: Connecting patients with support groups, either through national organizations like the National Psoriasis Foundation or the National Eczema Association or through local and online communities, can provide valuable social support. These groups offer a space for patients to share experiences and find encouragement from others facing similar challenges. 
  3. Interdisciplinary team: Leveraging an interdisciplinary approach, including mental health professionals and primary care providers, can address the holistic needs of patients. This team-based care model ensures that patients receive comprehensive support, addressing both their physical and emotional health. 

Touch starvation is a significant issue for patients with inflammatory skin diseases, impacting their quality of life and overall well-being. By understanding and addressing this issue, clinicians can improve patient care and outcomes. Regular follow-ups, intentional dialogue, and access to advanced treatments and support resources are essential for effectively managing touch starvation and enhancing the quality of life for these patients. For more resources, the National Psoriasis Foundation and the National Eczema Association offer valuable support and information for both patients and providers.

1
Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma
5:04

Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma

2
What Changes When We Treat Psoriasis as Systemic Disease?
7:01

What Changes When We Treat Psoriasis as Systemic Disease?

3
Who to Look for and When to Act
2:31

Who to Look for and When to Act

4
How Oral TYK2 Inhibition Is Showing Up in Real Decisions
10:38

How Oral TYK2 Inhibition Is Showing Up in Real Decisions

5
Injecting on Bone: A Practical Approach to Filler Safety
0:44

Injecting on Bone: A Practical Approach to Filler Safety

6
Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study
8:12

Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study

7
Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course
2:51

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

8
Fast Relief, Sustained Control: What Remibrutinib Shows in CSU
2:42

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

9
Bullous Pemphigoid: The Evolving Treatment Landscape
8:22

Bullous Pemphigoid: The Evolving Treatment Landscape

10
Confirming BP Diagnosis and Choosing Treatment
7:42

Confirming BP Diagnosis and Choosing Treatment

11
How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC
4:08

How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC

12
What Four Years Can Tell Us About Treating Moderate to Severe HS
3:29

What Four Years Can Tell Us About Treating Moderate to Severe HS

13
Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib
3:18

Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

14
A Review of Dermoscopy Techniques With Michelle Tarbox, MD
1:28

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

15
Leading With Intention in Aesthetic Assessment
2:57

Leading With Intention in Aesthetic Assessment

16
Recognizing Bullous Pemphigoid Earlier in Clinical Practice
1:52

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

17
Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration
10:34

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

18
Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso
23:00

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso

19
Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma
8:33

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

20
Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test
6:53

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

21
Topical Truths: Managing AD in the Real World
21:54

Topical Truths: Managing AD in the Real World

22
The Oral Conversation: How We Talk to Patients About Systemic Therapy Today
30:51

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

23
Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice
10:00

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

24
Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk
10:04

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

25
Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways
9:36

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

26
Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients
9:51

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

27
Fall Clinical Continuity Experience - Vtama - Lecture Recap Video
0:35

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

28
Four Years of Data: Durability and Distinction with TYK2 Inhibition
3:09

Four Years of Data: Durability and Distinction with TYK2 Inhibition

29
What an Oral Option Means for Psoriasis Care
2:34

What an Oral Option Means for Psoriasis Care

30
LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults
8:39

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

31
Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes
7:58

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

32
Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis
4:59

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

33
VTAMA: A New Standard in Psoriasis Management
4:59

VTAMA: A New Standard in Psoriasis Management

34
Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions
18:17

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions

35
Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice
16:27

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice

36
Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing
6:45

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing

37
Psoriasis mechanism of disease: Pathogenesis
8:27

Psoriasis mechanism of disease: Pathogenesis

38
Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors
12:45

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors

Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved